B2K Webinar – Wednesday June 19, 2019

On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The 5th webinar in this […]

Read Article


2018 CVC Annual Report

We are pleased to share the 2018 Canadian VIGOUR Centre (CVC) Annual Report. This year’s report highlights the results of our organization’s focus in 2018 and emphasizes our continuing commitment to enhancing human health through innovation and training the next generation of health researchers. Our staff and faculty have all contributed to this compendium and […]

Read Article


Spring 2019 Chronicle Published

We are pleased to share with you the Spring 2019 issue of the Canadian Cardiac Chronicle. This issue features: A letter from CVC Co-Director, Justin Ezekowitz, considering the complexity of clinical research, and the importance of providing sophisticated answers to simple questions Recent updates from current and upcoming clinical trials An overview of key ideas […]

Read Article


B2K Webinar – Wednesday May 1, 2019

On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The 4th webinar in this […]

Read Article


B2K Webinar – Wednesday February 27, 2019

On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The 3rd webinar in this […]

Read Article


B2K Webinar – Tuesday January 22, 2019

On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The second webinar in this […]

Read Article


Winter 2018 Chronicle Published

We are pleased to share with you the Winter 2018 issue of the Canadian Cardiac Chronicle. This issue features: A letter from Founding Director Dr. Paul W. Armstrong on the importance of reliable research and scientific literacy Recent updates from current and upcoming clinical trials Information about upcoming 2019 events, including ACC Rockies,the CVC Clinical […]

Read Article


New Associate Faculty Members – Drs. Sean McMurtry and Roopinder Sandhu

The CVC is pleased to announce the addition of two new associate faculty members. Dr. Sean McMurtry is a clinician scientist and Associate Professor in the Division of Cardiology. Dr. McMurtry is engaged in basic and clinical research projects studying coronary artery disease, peripheral artery disease, venous thromboembolism, and thoracic aortic disease. Dr. Roopinder Sandhu […]

Read Article


B2K18 Webinar – Tuesday December 4th, 2018

On behalf of the Canadian VIGOUR Centre (CVC) and the Beyond 2018 (B2K18) educational program, we are pleased to share a Canadian Cardiovascular Society-accredited webinar series initiative that is being provided as an extension to the B2K18 symposium (held annually during the Canadian Cardiovascular Congress, most recently October 22, 2018). The first webinar in this […]

Read Article


ODYSSEY OUTCOMES Published in the New England Journal of Medicine

Congratulations to the ODYSSEY OUTCOMES team on the publication of Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome in The New England Journal of Medicine. The ODYSSEY OUTCOMES clinical trial sought to determine whether alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary […]

Read Article